UBS analyst AJ Rice initiated coverage of Ardent Health (ARDT) with a Buy rating and $17 price target The company owns a “solid” portfolio of acute care hospitals with opportunity to continue growing its core commercial and Medicare lines of business, the analyst tells investors in a research note. The firm views the 25% pullback in shares year-to-date as an overreaction to Medicaid payment reductions that will take more than a decade to fully phase in.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health files $500M mixed securities shelf
- Ardent Health files to sell 120.45M shares of common stock for holders
- Ardent Health Partners, Inc.: Balancing Growth Potential and Regulatory Risks with a Hold Rating
- Ardent Health price target lowered to $15 from $18 at JPMorgan
- Ardent Health price target lowered to $23 from $24 at Leerink